CMS – Page 46 – medicarereport.org

Monday, December 22, 2025

Latest:

Eileen Cook August 28, 2023August 28, 2023 0 Comments CMS, medicare, Medicare Advantage, Medicare Part D

Nearly half of Medicare Advantage beneficiaries disenroll from their plans within 5 years: Study

(By Rylee Wilson for Becker’s Hospital Review) Many Medicare Advantage beneficiaries disenroll from their plans within five years of enrolling,

CMS Hospice/Home Health Services Medicare - General

Eileen Cook August 24, 2023August 24, 2023 0 Comments CMS, Hospice, medicare

CMS is Taking Action to Address Benefit Integrity Issues Related to Hospice Care

(Source – www.cms.gov/blog) Effective oversight and enforcement are important to protect the integrity of the Medicare program, especially for vulnerable,

CMS Health Care Finance Health Care Redesign Part D/Prescription Drugs

Eileen Cook August 22, 2023August 22, 2023 0 Comments CMS, Healthcare Costs, medicare, Medicare Part D, Out-of-pocket prescription costs

CMS pitches guidance for Medicare Part D monthly payment plan: 5 things to know

(By Rylee Wilson for Becker’s Hospital Review) CMS published draft guidance for a new program that will allow Medicare Part

CMS Medical Technology Medicare - General

Eileen Cook August 17, 2023August 17, 2023 0 Comments CMS, Genetic Counselors, Genetic testing, Medical Technology, medicare

Medicare beneficiaries deserve access to genetic counselors

(By Deepti Babu for STAT) Precision medicine driven by genetic health care is knocking on the door. It offers hope

CMS Health Care Finance Health Care Redesign Part D/Prescription Drugs

Eileen Cook August 16, 2023August 16, 2023 0 Comments CMS, Drug-pricing, Medicare Drug Price Negotiation Program, Medicare Part D

The 10 drugs that CMS might wrangle into negotiations

(By Paige Twenter for Becker’s Hospital Review) CMS plans to soon release its list of 10 drugs that are up

CMS Health Care Finance Medicare - General Medicare Advantage Part D/Prescription Drugs

Eileen Cook August 14, 2023August 14, 2023 0 Comments CMS, Enrollment, Healthcare Costs, medicare, Medicare Advantage, Medicare Part D

Medicare Advantage in 2023: Enrollment Update and Key Trends

(By Nancy Ochieng, Jeannie Fuglesten Biniek, Meredith Freed, Anthony Damico, and Tricia Neuman for the Kaiser Family Foundation Published: Aug

CMS Health Care Finance HHS Medicare Advantage Part D/Prescription Drugs

Eileen Cook August 11, 2023August 11, 2023 0 Comments CMS, Healthcare Costs, medicare, Medicare Advantage, Medicare Part D, Medicare Star Ratings

Medicare Advantage in 2023: Premiums, Out-of-Pocket Limits, Cost Sharing, Supplemental Benefits, Prior Authorization, and Star Ratings

(By Nancy Ochieng, Jeannie Fuglesten Biniek, Meredith Freed, Anthony Damico, and Tricia Neuman for the Kaiser Family Foundation Published: Aug

Affordable Care Act (ACA)CMS Health Care Finance Medicare - General Medicare Advantage

Eileen Cook August 10, 2023August 10, 2023 0 Comments ACA, CMS, Federal bonus payments, Healthcare Finance, medicare, Medicare Advantage, Medicare Advantage Star Ratings

Medicare Advantage Insurers Will Collect at Least $12.8 Billion in Federal Bonus Payments in 2023—a Nearly 30% Increase from 2022

(By Craig Palosky for Kaiser Family Foundation published August 9, 2023) Federal spending on bonus payments to insurance companies that

CMS Health Care Finance Health Care Redesign HHS Legislative Update Medicare - General Part D/Prescription Drugs

Eileen Cook August 9, 2023August 9, 2023 0 Comments CMS, Healthcare Costs, Healthcare Finance, HHS, Inflation Reduction Act of 2022, Medicare Part D

FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program

(By Juliette Cubanski for the Kaiser Family Foundation published August 8, 2023) The Inflation Reduction Act of 2022 (the Act),

Alzheimer's/Dementia Health Care Finance Medicaid Medicare - General Part D/Prescription Drugs

Eileen Cook August 2, 2023August 2, 2023 0 Comments Alzheimer's Disease, CMS, Donanemab, Dual Eligible, FDA, Lecanemab Drug, Medicaid, medicare, Medicare Part D, Older Adults

The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers

(By Arthur Allen for KFF Health News) The first drug purporting to slow the advance of Alzheimer’s disease is likely